12:50 AM EDT, 10/26/2026 (MT Newswires) -- Genmab (GMAB.CO) is teaming up with US biopharmaceutical company Incyte on a phase 1/2 clinical trial of a combination formulation to treat mutated metastatic colorectal cancer. The Danish biotechnology company said Oct. 24 that the trial will assess its investigational IgG1-bispecific antibody, plus Incyte's investigational, potent, and selective KRAS G12D inhibitor INCB161734, and standard-of-care chemotherapy as a first-line treatment for metastatic colorectal cancer with a KRAS G12D mutation. Genmab will oversee the study, with its partner providing co-funding and INCB161734.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.